In a Polarizing Category, Leadership Is Legitimacy

How experienced directors and operators help build credibility in emerging biotech categories

When Eli Lilly agreed to acquire AtaiBeckley for up to $2.8 billion, most of the coverage focused on the science and the price.

Both matter.

But the deal also signals something larger than a single transaction. It follows AbbVie’s move into the space months earlier, and analysts already expect additional large drugmakers to look closely at psychedelic assets with strong clinical data. A category that not long ago sat on the edge of the industry is now part of a serious institutional conversation.

The part of that story worth returning to is not just the molecule. It is the people who were willing to stand behind the category before the market was ready to.

The path from scientific promise to institutional credibility is, underneath it all, a leadership story.

Why Is It Hard to Recruit Directors into an Emerging Biotech Category?

Anything new has to earn credibility before the market fully understands it. In biotech, that credibility depends not only on the science, but also on the leaders willing to stand behind it before consensus forms.

In such categories, leaders are not just evaluating the science. They are evaluating the risk of attaching their name to something the broader market may not yet accept.

LifeSci Search saw this dynamic in its work with AtaiBeckley while helping to build its board. The talent was there, and the interest was often there too, but several highly qualified prospective board members still hesitated.

Not because they dismissed the science, but because they understood the weight of the category. Several experienced biotech and pharma leaders found the science compelling but paused over what attaching their names to the word “psychedelic” might signal to their networks.

What Experienced Leaders Bring to an Emerging Category

The two board members who ultimately joined saw both the risk and the potential. What made their involvement especially valuable was the experience they brought to a company changing alongside the category itself. Both had spent their careers leading through change and making difficult strategic decisions.

Laurent Fischer, former CEO of Adverum Bio and one of the directors who joined the board, put it this way: “Directors who have run companies and worked through complex therapeutic areas bring more than oversight. They can help CEOs think through situations they may be facing for the first time, particularly as disruptive technologies create new paths forward. That experience can also build credibility with larger pharmaceutical companies that see the potential in these markets but may not yet have the same depth of internal expertise.”

Scott Braunstein, former CEO of Marinus Pharmaceuticals and the other director who joined the board, saw another side of that need: “Atai was going through a major change when Laurent and I joined the board, moving from an investment company with an internal pipeline to a dedicated, integrated biotech, along with a major geographic shift from Europe to the U.S. That kind of transformation requires the board to evolve too, with directors who have the operating experience to help the CEO and leadership team make the strategic decisions and pivots required through that transition.”

Credibility is not just about who is willing to put their name behind an emerging category. It is also about the experience they bring when they do. This dynamic extends well beyond psychedelics. In any emerging category, experienced directors and operators can help bridge the gap between promising science and broader market confidence.

The Leaders Who Move First Help Shape the Category

Strong science creates the opportunity. But in an emerging category, the label can sometimes overshadow the company itself.

For experienced directors, the better question is not only how the market views the category, but whether their judgment can help the company make stronger decisions at a critical point. When the right leaders step in, their involvement can build external confidence while strengthening the decisions made inside the company.

Zach Charles | Managing Partner